SureTrader
Home > Boards > US OTC > Medical - Drugs > Innovation Pharmaceuticals Inc. (IPIX)

Brilacidin for Oral Mucositis is unlikely to be

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
KarinCA Member Profile
Member Level 
Followed By 529
Posts 23,312
Boards Moderated 2
Alias Born 11/16/07
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 1/11/2018 4:35:53 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 12/27/2017 3:08:40 PM
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) "Edgar (US Regulatory)" - 11/13/2017 10:03:05 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/8/2017 4:04:57 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 9/22/2017 6:02:17 AM
Securities Registration Statement (simplified Form) (s-3) "Edgar (US Regulatory)" - 9/11/2017 12:47:10 PM
Annual Report (10-k) "Edgar (US Regulatory)" - 9/11/2017 6:04:38 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 9/11/2017 6:04:37 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:27:18 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/6/2017 6:24:45 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/8/2017 4:18:08 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:33 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:17:00 PM
Annual Statement of Changes in Beneficial Ownership (5) "Edgar (US Regulatory)" - 8/8/2017 4:16:36 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/13/2017 4:04:10 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2017 4:19:05 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/9/2017 4:09:09 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 4/28/2017 12:50:45 PM
Bahamas Development Corp. (OTC Pink: BDCI) $2.4 Million in Sales and 10% Quarterly Growth – Issues Guidance "InvestorsHub NewsWire" - 4/17/2017 7:03:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/31/2017 4:25:24 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 3/29/2017 4:13:08 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 3/27/2017 11:29:27 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/16/2017 7:01:38 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 2/9/2017 4:04:17 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/9/2017 9:39:24 AM
KarinCA Member Level  Friday, 10/06/17 12:53:17 PM
Re: LilKahuna post# 199244
Post # of 213458 
Brilacidin for Oral Mucositis is unlikely to be spun off on its own. But, it will be interesting to watch how this all pans out. You could easily be correct.

Either way, the topline is likely to be in line with the spectacular interim results. I look forward to seeing them. ;)








In Reply to 'LilBigKahuna'
I don’t think Phase 3 can be skipped, though I hope the same. But, I do think B-OM will be licensed independently of the B platform since it is an oral rinse. That can easily come in the next quarter or two and for a very large upfront payment.





To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist